NEW YORK (GenomeWeb) – NanoString today said that its preliminary financial results for the fourth quarter and fiscal year ended December 31, 2018 are expected to beat its previously stated guidance, as well as the consensus Wall Street estimates.

NanoString said that product and service revenue is expected to be approximately $23.5 million for the fourth quarter of 2018, which would exceed the firm's previous guidance range of $22 to $23 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.